Evolent Health, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.9B | $2.6B | $2.0B | $1.4B | $908.0M |
| Operating income | -$410.1M | -$40.5M | -$71.2M | $3.6M | -$42.4M |
| Operating expenses | — | — | — | — | $950.4M |
| Cost of revenue | $1.5B | $2.2B | $1.5B | $1.0B | $657.6M |
| Cash from operations | $38.8M | $18.8M | $142.6M | -$11.6M | $38.7M |
| Capital expenditure | — | — | $137,000 | $573,000 | $784,000 |
| Free cash flow | — | — | $142.4M | -$12.1M | $38.0M |
| Share repurchases | $40.0M | $0 | $0 | — | — |
| Impairments | $398.0M | $0 | $0 | $0 | $0 |
| Total assets | $1.9B | $2.5B | $2.7B | $1.8B | $1.4B |
| Total liabilities | $1.5B | $1.4B | $1.4B | $957.9M | $725.8M |
Shares outstanding 112.5M · Free float 84.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.